Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Novo Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leading Wall Street analysts to downgrade the stock.
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
I'm downgrading Novo Nordisk from Strong Buy to Buy due to recent guidance cuts, competitive pressures, and persistent compounded GLP-1 drug erosion. The long-term obesity drug opportunity, Novo's manufacturing scale, and a strong pipeline still support a bullish multi-year thesis. Novo is attractively valued after the sell-off, but near-term recovery requires patience; it's a Buy for long-term investors comfortable with volatility.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $47, denoting a -6.06% move from the preceding trading day.
Novo Nordisk: Don't Miss Buying This Dip
Novo Nordisk's 20%+ price drop since yesterday following a significant downgrade in sales and profit guidance is a great buying opportunity. The stock's forward P/E is at half the stock's five-year average, and with growth catalysts in place, fundamentals could improve too. The launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO.
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
Novo Nordisk: After the profit warning what next?
Shares in Novo Nordisk (NYSE:NVO) are under the spotlight after a surprise profit warning, which, while denting the share price, failed to the wreak the damage some might have feared. That said, the 3.6% fall in the stock piles on the pain for the Ozempic maker, which was formerly Europe's most valuable company.
Novo Nordisk: Catch That Falling Knife
Novo Nordisk's stock has dropped over 20%, but its core business remains strong and diversified, making this an attractive entry point for investors. Despite increased GLP-1 competition and lowered guidance, Novo Nordisk continues to grow, expand its market share, and generate robust cash flow. The company's rare disease and oral semaglutide segments are showing promising growth, with a strong R&D pipeline supporting future expansion.
Novo Nordisk shares fall further as new CEO faces US challenges
Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value.
Novo Nordisk: Massive Overreaction Presents An Opportunity
Novo Nordisk's sharp selloff is an overreaction; long-term fundamentals remain solid despite lowered guidance and a sudden CEO change. US market headwinds, competitive pressure from Eli Lilly and telehealth, and regulatory loopholes are weighing on near-term growth. Novo Nordisk boasts a robust pipeline with promising obesity and diabetes drugs, including oral Wegovy and next-generation therapies.
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade, despite strong double-digit sales and profit growth. The market is concerned about headwinds for semaglutide (Wegovy/Ozempic), including supply issues, competition, and regulatory risks. Despite the selloff, I believe Novo remains undervalued given its dominant GLP-1 franchise, robust pipeline, and long-term growth potential.
Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%
Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen.
